Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
F2RL2 Biologics Sequence Review Report 2026: Proteinase-activated receptor 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of F2RL2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GRM8 Biologics Sequence Review Report 2026: Metabotropic glutamate receptor 8 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GRM8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
AIP Biologics Sequence Review Report 2026: AH receptor-interacting protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of AIP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD5 Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD5 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CD8A Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD8 alpha chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD8A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TNFRSF17 Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 17 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFRSF17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD79B Biologics Sequence Review Report 2026: B-cell antigen receptor complex-associated protein beta chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD79B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FCGR2C Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor II-c Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR2C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FCGR2B Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor II-b Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR2B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD247 Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 zeta chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD247 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GPR50 Biologics Sequence Review Report 2026: Melatonin-related receptor Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GPR50 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
KLRD1 Biologics Sequence Review Report 2026: Natural killer cells antigen CD94 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of KLRD1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
944
945
946
947
948
>>
2260
>